Andrew Aistrup advises clients on a broad range of UK intellectual property (IP) matters, with a particular focus on branding, patent, and copyright disputes. He also advises clients on life sciences regulatory issues, including pharmaceutical, medical device, clinical trial, and telehealth regulations. Andrew has experience working with multinational clients in a range of sectors, including digital gaming, aerospace, e-commerce, information technology (IT), consumer goods, and pharmaceuticals.
Andrew has acted in Commercial Court litigation regarding a high-value trademark license dispute and in various High Court litigation regarding alleged video game copyright infringement, misappropriation of trade secrets, patent infringement in aerospace and wireless communications, and trademark infringement. Andrew also regularly represents clients (both to defend and prosecute on behalf of clients' rights) for United Kingdom Intellectual Property Office (UKIPO) applications and proceedings, including trademark oppositions, cancellation actions, and in the drafting of trademark applications and risk assessments.
Andrew is a member of the British Literary and Artistic Copyright Association (BLACA) and has completed the University of Oxford Intellectual Property Law and Practice postgraduate course, which covered a wide range of intellectual property rights and commercial issues.
经验
- University of Oxford (Postgraduate Diploma [PGDip.] in Intellectual Property Law and Practice 2022); BPP Law School, Holborn (Legal Practice Course 2018); University College London (LL.M. in Corporate Law 2016); Christ's College, University of Cambridge (M.A. in Law 2014)
- Solicitor of the Senior Courts of England and Wales
发送前请注意
*Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice